ResearcherGuiyang Medical UniversityActive in the last 2 years
Yuting Guo
Matched on ORCID iD 0000-0002-8919-0888; OpenAlex author ID A5090967945. Sources: OpenAlex.
Their work
- Papers
- 3 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 6
2022: 1 paper · 2023: 1 paper · 2024: 1 paper
Papers 3
- Transcription factor KLF9 inhibits the proliferation, invasion, and migration of pancreatic cancer cells by repressing KIAA1522. Co-author DOI 10.1111/ajco.14048↗
- Exosomal miR-125b-5p derived from cancer-associated fibroblasts promotes the growth, migration, and invasion of pancreatic cancer cells by decreasing adenomato… Co-author DOI 10.21037/jgo-23-198↗
- CAV2 Regulates Mir-4723/Wnt7A Signalling Axis through Endocytosis and Epithelial-Mesenchymal Transition to Promote Proliferation, Invasion, and Metastasis of P… First author DOI 10.7150/jca.69617↗
Closest collaborators
The 6 strongest of 6 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chengyi Sun · 2 shared papers, 2022–2023 · strength 0.51
- Paper Exosomal miR-125b-5p derived from cancer-associated fibroblasts promotes the growth, migration, and invasion of pancrea… DOI 10.21037/jgo-23-198↗
- Paper CAV2 Regulates Mir-4723/Wnt7A Signalling Axis through Endocytosis and Epithelial-Mesenchymal Transition to Promote Prol… DOI 10.7150/jca.69617↗
- She Tian · 2 shared papers, 2022–2024 · strength 0.46
- Paper Transcription factor KLF9 inhibits the proliferation, invasion, and migration of pancreatic cancer cells by repressing … DOI 10.1111/ajco.14048↗
- Paper CAV2 Regulates Mir-4723/Wnt7A Signalling Axis through Endocytosis and Epithelial-Mesenchymal Transition to Promote Prol… DOI 10.7150/jca.69617↗
- Shi Zuo · 1 shared paper, 2024 · strength 0.26
- Chao Yu · 1 shared paper, 2024 · strength 0.26
- Cheng-Yi Sun · 1 shared paper, 2024 · strength 0.26
- Dan Li · 1 shared paper, 2022 · strength 0.20
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.